Jefferies is bullish on 6 healthcare stocks with upside potential of up to 46%. Own any?

Hospital stocks including Fortis Healthcare, Dr Agarwal’s, Manipal, Apollo Hospitals and Medanta extended their losses for a second straight session on Thursday, after falling as much as 10% in the previous session, as the Supreme Court questioned steep markups on cancer drugs and asked the government to examine allegations that hospitals require patients to purchase medicines from their own or…

Written by
Veer Sharma
Published by
The Economic Times
Published
Length
426 words · 2 min
Jefferies is bullish on 6 healthcare stocks with upside potential of up to 46%. Own any?
Benchmarks Nifty22,421.95-198.5FEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return19.6 % Invest NowEnter search text:Jefferies is bullish on 6 healthcare stocks with upside potential of up to 46%. Own any?Written by Veer Sharma, ETMarkets.com|Oct 02, 2026, 10:48:54 AM IST1/7

Hospital stocks in focus

Hospital stocks including Fortis Healthcare, Dr Agarwal’s, Manipal, Apollo Hospitals and Medanta extended their losses for a second straight session on Thursday, after falling as much as 10% in the previous session, as the Supreme Court questioned steep markups on cancer drugs and asked the government to examine allegations that hospitals require patients to purchase medicines from their own or designated pharmacies. However, Jefferies sees this as an excellent entry point to buy these 6 stocks.

Agencies2/7

Apollo Hospitals

Jefferies has a Buy rating on Apollo Hospitals with a target price of Rs 10,350, implying 27% upside, while its FY26E-29E EBITDA CAGR is estimated at 20%.

TNN3/7

Dr Agarwal’s Healthcare

Jefferies has a Buy rating on Dr Agarwal’s Healthcare with a target price of Rs 600, implying 25% upside, while its FY26E-29E EBITDA CAGR is estimated at 23%.

ETMarkets.com4/7

Fortis Healthcare

Jefferies has a Buy rating on Fortis Healthcare with a target price of Rs 1,125, implying 46% upside, while its FY26E-29E EBITDA CAGR is estimated at 17%.

Agencies5/7

Max Healthcare

Jefferies has a Buy rating on Max Healthcare with a target price of Rs 1,260, implying 36% upside, while its FY26E-29E EBITDA CAGR is estimated at 18%.

ETMarkets.com6/7

Manipal Health Enterprises

Jefferies has a Buy rating on Manipal Health Enterprises with a target price of Rs 870, implying 23% upside, while its FY26E-29E EBITDA CAGR is estimated at 19%.

7/7

Medanta

Jefferies has a Buy rating on Medanta with a target price of Rs 1,660, implying 22% upside, while its FY26E-29E EBITDA CAGR is estimated at 22%.


Disclaimer: This article has been written by Veer Sharma, who is not a SEBI-registered Research Analyst or an Investment Adviser. Veer Sharma and his ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here.

ETtechRead more onHospital stockshealthcare stocksApollo HospitalsDr Agarwal’s HealthcareFortis HealthcareMax HealthcareManipal Health EnterprisesMedantaJefferiesEnter search text:BrowseCompanies:ABCDEFGHIJKLMNOPQRSTUVWXYZ123456789
Hospital stocks in focus
Apollo Hospitals
Dr Agarwal’s Healthcare
Fortis Healthcare
Max Healthcare

Where this came from

This story was reported by Veer Sharma and first published by The Economic Times on 2 October 2026. HUE Legacy Ventures did not write it.

Carried in full with attribution and a link to the original. Rights remain with the publisher, who may request removal at any time.

Read it at economictimes.indiatimes.com →